Frontline Therapies Archives

January 6, 2023

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

January 6, 2023

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with

September 13, 2022

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).

August 26, 2022

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable

August 25, 2022

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data of the fixed duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (treatment) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

July 6, 2022

Impact of Low-Burden TP53 Mutations in the Management of CLL

Chronic Lymphocytic Leukemia (CLL) is a heterogeneous illness with a variable clinical course primarily determined by the disease’s underlying genetics, which is not the same for each affected individual. However, one gene that is highly important in predicting the natural history of CLL and response to chemoimmunotherapy is TP53,

June 30, 2022

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

While this oral medication has dramatically improved the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), there is concern about the risk of heart or cardiovascular (CV) adverse effects due to off-target kinase inhibition.

June 21, 2022

ASH 2021: Dr. Nitin Jain on First-Line Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Chronic Lymphocytic Leukemia (CLL)

At the American Society of Hematology (ASH) 2021, Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center, interviewed Dr. Nitin Jain, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. They discussed early results from an ongoing study

June 15, 2022

ASH 2021: Dr. Nitin Jain on First-Line Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia (CLL) with TP53 Mutations

Discussion of outcomes for patients with del(17p) or TP53 mutations who have been treated with first-line BTK inhibitors such as ibrutinib or acalabrutinib.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Frontline Therapies

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

Impact of Low-Burden TP53 Mutations in the Management of CLL

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

ASH 2021: Dr. Nitin Jain on First-Line Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Dr. Nitin Jain on First-Line Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia (CLL) with TP53 Mutations

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT